01 1 Imusera
02 10Gilenya
03 3Imusera
04 1Royalty From Gilenya
05 7Royalty from Gilenya
Main Therapeutic Indication : Neurology
Currency : USD
2020 Revenue in Millions : 38
2019 Revenue in Millions : 0
Growth (%) : 100
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 40
2019 Revenue in Millions : 88
Growth (%) : -55
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 3,003
2019 Revenue in Millions : 3,223
Growth (%) : -7
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 35
2020 Revenue in Millions : 39
Growth (%) : -2
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 2,787
2020 Revenue in Millions : 3,003
Growth (%) : -7
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 33
2020 Revenue in Millions : 37
Growth (%) : -5
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 2,013
2021 Revenue in Millions : 2,787
Growth (%) : -28
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 971
2021 Revenue in Millions : 30
Growth (%) : 3,097
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 7
2021 Revenue in Millions : 32
Growth (%) : -79
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 925
2022 Revenue in Millions : 2,013
Growth (%) : -54
LOOKING FOR A SUPPLIER?